This article was originally published in The Rose Sheet
Acquisition of tissue engineering company SkinEthic by French beauty marketer's Episkin subsidiary, which is dedicated to development of reconstructed skin, is aimed at helping L'Oréal enhance development of in vitro test methods, firm says in Feb. 28 release. SkinEthic is an "important worldwide player in the production and commercialization of human epidermal and epithelial tissues," including epidermis, dermis and corneal tissues, L'Oréal notes. "The acquisition of SkinEthic allows us to respond to the needs of the entire industry and more specifically in the area of alternative approaches to animal testing," firm adds. Marketing of most cosmetic products tested on animals is prohibited under 7th Amendment to EU's Cosmetics Directive beginning in 2009...
You may also be interested in...
A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.
Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.